Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. PET/MRI for Preoperative Planning in Patients with Soft Tissue Sarcoma: A Technical Report of Two Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Massive fetomaternal hemorrhage caused by an intraplacental choriocarcinoma: a case report

    Research output: Contribution to journalJournal articleResearch

  1. Brain tumours in children and adolescents may affect the circadian rhythm and quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Intestinal permeability in type 1 diabetes: An updated comprehensive overview

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

A 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for insulin quickly declined, and she took her last dose of insulin 19 days after the first dose of fenofibrate, having regained endogenous control of blood glucose concentrations. She has now been insulin independent for one year and 9 months. Unstimulated C-peptide has increased by 51% (317 to 479 pmol/l), and IA-2 autoantibody level has decreased by 65% (49 to 17 × 103 arbitrary units). Fenofibrate is a widely used drug for reducing triglyceride and cholesterol levels. Fenofibrate reverses and prevents autoimmune diabetes in nonobese diabetic (NOD) mice by increasing the amount of the sphingolipid sulfatide in islets. Sphingolipid metabolism is otherwise abnormal in the islets at diagnosis of type 1 diabetes. In conclusion, we describe a 19-year-old patient with classical newly diagnosed type 1 diabetes, which following fenofibrate treatment has been without insulin for 21 months.

Original languageEnglish
Article number6865190
JournalCase reports in medicine
Volume2020
Pages (from-to)6865190
ISSN1687-9627
DOIs
Publication statusPublished - 2020

ID: 60645890